← back to search

Jiaheng Qiu

NGM Biopharmaceuticals (United States) · US
Area of research
Genetics · Health, Toxicology and Mutagenesis
Research interest
Research interests include Glioma Diagnosis and Treatment, Air Quality and Health Impacts, Cancer Immunotherapy and Biomarkers, and Melanoma and MAPK Pathways.
h-index
18
citations
3,134
works
39
NIH funding
primary concept
email

Recent publications

Growth recovery in patients with <i>BRAF</i> altered pediatric low-grade gliomas (LGG) after discontinuation of tovorafenib.
Journal of Clinical Oncology 2025cited by 1position: middledoi
LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration
BMC Cancer 2024cited by 58position: middledoi
Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial
Neuro-Oncology 2024cited by 10position: middledoi
LGG-40. TYPE II RAF INHIBITOR TOVORAFENIB IN RELAPSED/REFRACTORY PEDIATRIC LOW-GRADE GLIOMA (PLGG): REVERSIBLE DECREASES IN GROWTH VELOCITY IN THE PHASE 2 FIREFLY-1 TRIAL
Neuro-Oncology 2024cited by 1position: middledoi
LOGGIC/FIREFLY-2: A phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating <i>RAF</i> alteration.
Journal of Clinical Oncology 2023cited by 5position: middledoi
CTNI-24. CLINICAL ACTIVITY AND SAFETY OF THE RAF INHIBITOR TOVORAFENIB IN PATIENTS WITH OPTIC PATHWAY GLIOMAS IN THE REGISTRATIONAL PEDIATRIC LOW-GRADE GLIOMA ARM OF THE PHASE 2 FIREFLY-1 (PNOC026) STUDY
Neuro-Oncology 2023cited by 2position: middledoi
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
Nature Medicine 2018cited by 1,242position: middledoi
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
Nature Medicine 2018cited by 38position: middledoi
IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun).
Journal of Clinical Oncology 2017cited by 74position: middledoi
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial
The Lancet Oncology 2016cited by 293position: middledoi
ORAL01.04: Phase II Trial of Atezolizumab for Patients with PD-L1–Selected Advanced NSCLC (BIRCH): Updated Efficacy and Exploratory Biomarker Results
Journal of Thoracic Oncology 2016cited by 15position: middledoi
Prenatal air pollution exposure and ultrasound measures of fetal growth in Los Angeles, California
Environmental Research 2014cited by 64position: middledoi
Childhood Cancer and Traffic-Related Air Pollution Exposure in Pregnancy and Early Life
Environmental Health Perspectives 2013cited by 146position: middledoi
Risk of leukemia in relation to exposure to ambient air toxics in pregnancy and early childhood
International Journal of Hygiene and Environmental Health 2013cited by 118position: middledoi
Retinoblastoma and ambient exposure to air toxics in the perinatal period
Journal of Exposure Science & Environmental Epidemiology 2013cited by 48position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Julia E. Heck · University of North Texas3 papers (2013–2013)Myles Cockburn · University of Southern California3 papers (2013–2013)Beate Ritz · University of California, Los Angeles3 papers (2013–2014)Michelle Wilhelm · Angeles University Foundation2 papers (2013–2014)Andrew S. Park · AbbVie (United States)2 papers (2013–2013)Pablo Hernáiz Driever · German Center for Pediatric and Adolescent Rheumatology2 papers (2023–2025)Lindsay Kilburn · Columbia University Irving Medical Center2 papers (2023–2025)Gallia G. Levy · Atotech (United States)1 papers (2016–2016) · 1 papers (2016–2016)Lisa McLeod · University of Colorado Denver1 papers (2025–2025)Peter Schmid · Cancer Research Institute1 papers (2016–2016)Olaf Witt · St. Jude Children's Research Hospital1 papers (2023–2023) · 1 papers (2025–2025) · 1 papers (2016–2016)David F. McDermott · Dana-Farber/Harvard Cancer Center1 papers (2017–2017)Mario Sznol · Yale Cancer Center1 papers (2017–2017)Chee‐Keong Toh · National University of Singapore1 papers (2016–2016)Bohuslav Melichar · Cancer Research UK1 papers (2016–2016)Daniel Landi · Duke University1 papers (2025–2025)Jun Wu · University of California System1 papers (2013–2013)